Filing Flows › Cytosorbents (CTSO) › Q2 2026 › vs Q2 2025
Cytosorbents (CTSO) Q2 2026 vs Q2 2025 (year over year)
Cytosorbents's revenue rose $16K (+0.2%) from $9.6M in Q2 2025 to $9.6M in Q2 2026.
Cytosorbents, Q2 2026: revenue $9.6M (+0.2% year over year), operating margin -27.4%, net loss $4.4M, operating cash flow −$583K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.6M | $9.6M | $16K | +0.2% |
| Net loss | $4.4M | −$1.9M | $6.4M | — |
| Costs & expenses | $14.1M | $15.2M | −$1.1M | -7% |
| Operating costs | $12.3M | $13.2M | −$961K | -7% |
| Interest & other, net | $1.8M | −$5.6M | $7.3M | — |
| Cost of revenue | $2.6M | $2.8M | −$219K | -8% |
| Research & development | $1.5M | $1.3M | $191K | +15% |
| SG&A | $8.0M | $9.2M | −$1.2M | -13% |
| Operating cash sources | $4.4M | −$1.9M | $6.4M | — |
| Depreciation & amortization | $360K | $280K | $80K | +28% |
| Share-based compensation | $368K | $571K | −$203K | -36% |
| Working capital & other | $3.1M | −$4.3M | $7.4M | — |
| Cash used in operations | $583K | $1.5M | −$926K | -61% |
| Net loss absorbed | $4.4M | −$1.9M | $6.4M | — |
Questions
How much did Cytosorbents's revenue grow year over year in Q2 2026?
Cytosorbents's revenue rose $16K (+0.2%) from $9.6M in Q2 2025 to $9.6M in Q2 2026.